28. A 49-year-old woman and her very anxious husband present to your office with progressively worsening sensory loss and weakness, which began distally in her legs and moved proximally beginning approximately a week ago. You notice she has a diffuse macular rash that is pruritic and scaling on her palms and soles. Records indicate that she had presented to the emergency department 3 weeks prior with complaints of severe nausea, vomiting, and diarrhea, and the physician had noted that her breath smelled strongly of garlic. What do you suspect is the cause for these symptoms?
a. Guillain-Barré syndrome
b. Cyanide poisoning
c. Thallium poisoning
d. Arsenic poisoning
e. Mercury poisoning
29. For the patient depicted in question 28, what test finding would have confirmed your suspicion if it had been completed during her emergency department visit 3 weeks prior?
a. LP revealing albumino-cytologic dissociation
b. Elevated urinary arsenic level
c. Elevated urinary thallium level
d. Elevated urinary mercury level
e. Elevated urinary cyanide level
28. d, 29. b
This patient exhibits symptoms consistent with arsenic poisoning. Arsenic is a naturally occurring element most commonly incorporated into organic or inorganic compounds, both of which are very toxic. It can also occur in gas form. With acute exposure, symptoms may develop within minutes to hours and usually begin with gastrointestinal symptoms such as abdominal pain, nausea, vomiting, and diarrhea. A garlic odor on the breath is characteristic. These symptoms can be followed by hypotension, dehydration, and cardiac and respiratory instability. Delirium, encephalopathy, coma, and seizures may occur. Other acute manifestations include proteinuria, hematuria, and acute tubular necrosis. If patients survive, within 1 to 3 weeks, they can develop hepatitis, pancytopenia, and a symmetric sensorimotor peripheral neuropathy, which typically begins with distal paresthesias, followed rapidly by an ascending sensory loss and weakness, which mimics Guillain-Barré syndrome. The neuropathy can progress to intense burning pain, especially in the soles. In addition, dermatologic lesions can occur and may include alopecia, oral mucosal ulcerations, diffuse pruritic macular rash, and scaly rash on the palms and soles. A dry hacking cough and Mees lines (horizontal 1- to 2-mm white lines on the nails) may also occur. In chronic poisoning, the peripheral neuropathy and dermatologic symptoms are usually more prominent than the gastrointestinal symptoms. Cancers of the liver, bladder, kidney, skin, lung, nasal mucosa, and prostate have been reported with chronic exposure.
After a suspected acute ingestion of arsenic, abdominal radiographs may reveal gastrointestinal radiopaque material. Urine arsenic levels are preferable to blood arsenic levels, but both can be used. Fish or shellfish intake within the previous 48–72 hours can cause falsely elevated levels of arsenic. For chronic exposure, hair and nail samples can be analyzed for the presence of arsenic, and 24-hour urine arsenic or spot urine arsenic and creatinine levels can be checked. Additional evaluations should include renal and liver function tests, complete blood cell count, urinalysis, and electrodiagnostic testing if there are symptoms of peripheral neuropathy. A distal sensorimotor axonopathy is the typical finding.
Acute treatment includes fluid and electrolyte replacement, cardiac monitoring, activated charcoal, and chelation therapy. Chelation agents typically used include dimercaprol (British Anti-Lewisite) and meso-2,3-dimercaptosuccinic acid (succimer).
Although symptoms can mimic Guillain-Barré syndrome, the constellation of clinical symptoms and signs described and adequate evaluation should have ruled this out. Cyanide and mercury poisoning are discussed in questions 30 and 31 respectively. Thallium causes acute gastrointestinal symptoms, confusion, painful (mostly sensory) neuropathy with autonomic features, and alopecia, which classically occurs about 2 to 4 weeks after ingestion.
Danan M, Dally S, Conso F. Arsenic-induced encephalopathy. Neurology. 1984; 34:1524.
Flomenbaum N, Goldfrank L, Hoffman R, et al. Goldfrank’s Toxicologic Emergencies, 8th ed. New York, NY: McGraw-Hill; 2006.
Windebank AJ. Arsenic. In: Spencer PS, Schaumburg HH (Eds), Experimental and Clinical Neurotoxicology. New York, NY: Oxford University Press; 2000.
Yip L, Dart RC. Arsenic. In: Sullivan JB, Krieger GR (Eds), Clinical Environmental Health and Toxic Exposures. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.